Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pearls & Myths: Experts Offer Advice & Dispel Myths

Thomas R. Collins  |  Issue: March 2020  |  February 25, 2020

ATLANTA—A key sign of myositis can be mechanic’s hands on the thumb side of a patient’s index finger. Patients with giant cell arteritis (GCA) shouldn’t have to try prednisone before tocilizumab. Rituximab at fixed intervals is not essential for the remission of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. In a session at the 2019 ACR/ARP Annual Meeting, two rheumatology experts shared these and other pearls of wisdom to help rheumatologists in the clinic, while also dispelling common myths.

Cautioning that new discoveries may make “today’s pearls tomorrow’s myths,” John Stone, MD, director of clinical rheumatology at Massachusetts General Hospital, Boston, offered the following myth-busting observations and tips.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Myth: Temporal artery biopsy is the gold standard for the diagnosis of GCA.

“With modern imaging and the incredible techniques we have with PET [positron-emission tomography], ultrasound, CTA [computed tomography angiogram] and MRA [magnetic resonance angiogram], we know patients who have large vessel involvement and may not have temporal involvement at all. And there are many reasons temporal artery biopsies can be negative,” Dr. Stone said. “The key diagnostic test in a patient with possible GCA is the history. A carefully taken history is the rheumatologist’s scalpel.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Pearl: A dry cough can be a symptom of occult GCA. “For patients who are over the age of 50 with any complaint above the head and neck who have signs of inflammation, GCA needs to be considered,” he said.

Myth: Tocilizumab should be reserved for GCA patients for whom prednisone has failed. Dr. Stone pointed to the GIACTA trial results, which showed the prednisone-only group sustained remission in only 14% or 18% of GCA cases, depending on the study group, compared with more than 50% of GCA cases for the tocilizumab groups.1

“It’s crazy to think about using a drug that’s going to fail most of the time—and is toxic—as the only starting approach to treating this [disease],” Dr. Stone said.

Pearl: Tongue ulcers in GCA occur on the lateral portion of the mid-tongue. The same goes for granulomatosis with polyangiitis (GPA).

Myth: Patients with ANCA-associated vasculitis require fixed intervals of B-cell depletion to maintain remission. Spacing treatment out at increasingly longer intervals—first four months, then six months and then eight months, for example—can accomplish the same goal, Dr. Stone said.

GPA & Beyond

Pearl: GPA can cause a facial droop. This effect occurs because the seventh cranial nerve runs through the middle ear space. When patients with GPA get otitis media and granulomatous inflammation in the middle ear, the nerve can compress, leading to a facial droop, he said.

Pearl: Churg-Strauss granulomas (cutaneous extravascular necrotizing granuloma)—typically on the elbows—are a common cutaneous manifestation of GPA. “You have to examine patients for these,” Dr. Stone said. “They don’t hurt. Patients will not notice them. But they’re a key clue to the possibility of GPA.”

Page: 1 2 3 | Single Page
Share: 

Filed under:CareerCareer DevelopmentMeeting ReportsProfessional Topics Tagged with:2019 ACR/ARP Annual Meeting

Related Articles

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

    Case Report: Giant Cell Arteritis-Related Stroke

    September 10, 2023

    Thromboembolic events are major contributors to the morbidity and mortality of patients with giant cell arteritis (GCA), but little is known about how GCA may increase the risk of ischemic strokes. GCA-related stroke is described as an ischemic cerebral infarct occurring within three to four weeks of GCA diagnosis and treatment. It occurs in 3–7%…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    September 18, 2017

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences